Two PSMA PET Tracers Match Each Other and Outperform MRI in Detecting Prostate Tumours

For men facing surgery for high-risk prostate cancer, one of the most consequential questions is deceptively simple: where exactly is the tumour? Surgeons who can answer it precisely can spare the delicate nerve bundles that control erectile function and urinary continence; surgeons who cannot must operate more broadly, trading function for certainty. A new prospective study from Aalborg University Hospital in Denmark now offers one of the most rigorous answers yet, comparing two radioactive tracers used in PSMA PET imaging head-to-head against multiparametric MRI, with the entire removed prostate examined slice by slice as the definitive reference standard.

The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, enrolled fifty men with biopsy-proven high-risk prostate cancer scheduled for robot-assisted radical prostatectomy between January 2022 and July 2024. Every participant underwent both [18F]F-PSMA-1007 PET/CT and [68Ga]Ga-PSMA-11 PET/CT before surgery, and forty-five also received multiparametric MRI after a protocol amendment added it as an exploratory third modality. The researchers then mapped tumours across six anatomical sextants of the prostate—base, mid-gland and apex on each side—using whole-mount histopathology of the entirely embedded surgical specimen, in which the gland is sectioned into 5 to 6 millimetre slices, embedded in paraffin, cut at 4 to 5 micrometres and stained for microscopic examination by two blinded uropathologists.

The underlying biology makes PSMA PET a compelling candidate for this task. Prostate-specific membrane antigen is a protein abundantly displayed on the surface of prostate cancer cells, and radiolabelled ligands that bind it allow clinicians to visualise tumour deposits as bright focal spots against dimmer background tissue. The two tracers differ chemically: gallium-68 is produced in a generator and has a half-life of just over an hour, while fluorine-18 offers a longer half-life of about 110 minutes, lower positron energy that yields sharper images, and reduced urinary excretion that can keep the bladder from obscuring the prostate. These theoretical advantages have fuelled a long-standing debate about which ligand clinicians should prefer.

The Danish team’s answer, at least within this cohort, is that it barely matters. At the patient level, [18F]F-PSMA-1007 PET/CT detected clinically significant prostate cancer—defined as grade group 3 or higher, or grade group 2 with a tertiary Gleason pattern 5—with 98 percent sensitivity and 96 percent diagnostic accuracy. [68Ga]Ga-PSMA-11 achieved 100 percent sensitivity and 98 percent accuracy, while MRI reached 96 percent sensitivity and 93 percent accuracy. No statistically significant difference separated the two PSMA ligands. The single apparent false-positive PET finding turned out to reflect tracer uptake in lower-grade, clinically insignificant cancer rather than benign tissue, underscoring how faithfully PSMA signal tracks with malignant biology even when it overshoots the clinical threshold.

The regional analysis told a more nuanced story. Of 300 prostate sextants, 205 contained clinically significant cancer. [18F]F-PSMA-1007 correctly identified clinically significant disease in 143 sextants, yielding a mixed-model accuracy of 69.8 percent, while [68Ga]Ga-PSMA-11 detected 136 sextants with 67.8 percent accuracy. MRI, evaluated across 270 sextants, achieved 62.9 percent accuracy. The statistical modelling, which used mixed-effects regression with a random intercept per patient to account for the clustering of repeated measurements within each prostate, revealed a striking trade-off: both PSMA tracers were significantly more sensitive than MRI, at roughly 70 percent versus 51 percent, but MRI was significantly more specific, at nearly 89 percent versus about 68 percent for the PET ligands. In other words, PSMA PET finds more of the tumour, while MRI makes fewer false alarms.

That complementarity is the study’s most clinically resonant finding. MRI, the current guideline-endorsed standard for tumour localisation and surgical planning, excels at anatomical detail but can miss lesions obscured by motion artefacts, hip prostheses, or inflammation, and it systematically underestimates tumour extent. PSMA PET, by contrast, lights up malignant tissue with high tumour-to-background contrast but flags some regions that turn out to harbour only low-grade disease. The authors argue that the two technologies may work best together, a conclusion that aligns with emerging multimodal approaches in which artificial intelligence models integrate PSMA PET, MRI, and clinical variables to predict adverse pathology before surgery.

Where both technologies stumbled was in staging tumour extension beyond the prostate gland. Extraprostatic extension was present in 26 of the 50 patients, yet sensitivity for detecting it was a dismal 12 percent for [18F]F-PSMA-1007, 23 percent for [68Ga]Ga-PSMA-11, and 9 percent for MRI. Seminal vesicle invasion, present in ten patients, fared somewhat better but still poorly, with both PET tracers reaching 30 percent sensitivity and MRI 14 percent—though specificity was nearly perfect, meaning that when any modality did call invasion, it was almost always right. These sobering numbers suggest that neither PSMA PET nor MRI is ready to replace histopathological assessment for local T-staging, and that surgical decisions about nerve-sparing must still rest on a synthesis of imaging, biopsy data and clinical judgement.

The study’s methodological rigour deserves emphasis. It followed STARD reporting guidelines, was registered in the EudraCT database, and was monitored under Good Clinical Practice. Readers were blinded to clinical data, histopathology and the other imaging modalities, and each reader interpreted only a single modality, with equivocal findings resolved by consensus. The researchers applied the PROMISE standardised reporting criteria for PSMA PET, using the liver as the reference background for the gallium tracer and the spleen for the fluorine tracer, and scored MRI lesions with PI-RADS version 2.1, counting regions as positive only at scores of 4 or higher. A neighbouring-region approach was used to minimise spatial mismatch between in-vivo imaging and ex-vivo pathology, acknowledging the tissue deformation and shrinkage that inevitably occur between scanning and sectioning.

The authors are careful about what their results do and do not prove. The study was designed to detect differences between modalities, not to formally demonstrate equivalence, so the absence of a statistically significant gap between the two PSMA ligands should not be read as proof of interchangeability. The single-centre design, the modest sample size, and the enrolment of patients from a high-volume tertiary centre all limit generalisability, and the MRI comparison was exploratory rather than prespecified. Still, the head-to-head design within the same patients, validated against whole-mount histopathology, is rare, and the findings provide hypothesis-generating evidence that both ligands perform comparably for intraprostatic localisation.

The implications ripple outward as PSMA PET expands from its established role in staging recurrent and metastatic disease toward primary tumour characterisation. If fluorine-18 and gallium-68 tracers deliver comparable intraprostatic performance, supply chains, costs and local production capacity may weigh more heavily in tracer selection than diagnostic nuance. Meanwhile, the demonstrated sensitivity advantage of PSMA PET over MRI, paired with MRI’s specificity edge, strengthens the case for hybrid and multimodal strategies that fuse molecular and anatomical information. As deep-learning models increasingly promise individualised risk stratification from combined imaging, this study supplies an essential foundation: a carefully validated account of what each modality, and each tracer, can and cannot see inside the prostate gland.

Subject of Research: Head-to-head comparison of two PSMA PET tracers and MRI for detecting and localising clinically significant prostate cancer against histopathology

Article Title: Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study

Article References: Gossili, F., Harving, F., Petersen, A. C., Madsen, C., Bouchelouche, K., Bruun, N. H., Leusink, R. J., Ahmed, A., Laursen, A. M., & Zacho, H. D. (2026). Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08191-9

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08191-9

Keywords: PSMA PET, prostate cancer, PET/CT, multiparametric MRI, F-18 PSMA-1007, Ga-68 PSMA-11, histopathology, tumour localisation, diagnostic accuracy, radical prostatectomy, nuclear medicine, PI-RADS